Berubicin was granted Orphan Drug Designation by FDA for the treatment of malignant gliomas.
Berubicin is sponsored by CNS Pharmaceuticals Inc.
In the phase I trial of Berubicin to treat glioblastoma under a prior developer, 44% of the patients demonstrated a significant improvement in progression-free survival, and one patient experienced a complete response.